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Blood vessels are essential components for many tissues and organs. Thus, efficient induc-
tion of endothelial cells (ECs) from human pluripotent stem cells is a key method for generat-
ing higher tissue structures entirely from stem cells. We previously established an EC
differentiation system with mouse pluripotent stem cells to show that vascular endothelial
growth factor (VEGF) is essential to induce ECs and that cyclic adenosine monophosphate
(cAMP) synergistically enhances VEGF effects. Here we report an efficient and robust EC
differentiation method from human pluripotent stem cell lines based on a 2D monolayer,
serum-free culture. We controlled the direction of differentiation from mesoderm to ECs
using stage-specific stimulation with VEGF and cAMP combined with the elimination of non-
responder cells at early EC stage. This “stimulation-elimination” method robustly achieved
very high efficiency (>99%) and yield (>10 ECs from 1 hiPSC input) of EC differentiation,
with no purification of ECs after differentiation. We believe this method will be a valuable
technological basis broadly for regenerative medicine and 3D tissue engineering.
Introduction
Blood vessels play essential roles in the generation of higher tissue structures, especially large
tissue and organ structures. The importance of endothelial cells (ECs) has already been shown
in the formation of various organs such as heart[1–3], liver[4–7], kidney[8], bone[9], and skin
among many others[10–13]. Thus, efficient EC preparation methods that provide scalable and
stable supply are necessary for three-dimensional (3D) tissue engineering and organ regenera-
tion. Human pluripotent stem cells are one of the most suitable sources for such purpose.
Previously, using mouse embryonic stem cells (ESCs), we established a method for system-
atic induction of cardiovascular cells from vascular endothelial growth factor (VEGF) recep-
tor-2 (VEGFR2)-positive mesoderm cells as cardiovascular progenitors[14,15]. VEGF/
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VEGFR2 signaling is essential for inducing EC differentiation from VEGFR2-positive meso-
derm cells. Furthermore, we also found that cyclic adenosine monophosphate (cAMP) signal-
ing potently enhances EC differentiation[16,17] and that activation of a major downstream
molecule of cAMP, protein kinase A (PKA), increased the expression of VEGFR2 and another
VEGF receptor, neuropilin1, which together form a specific receptor for the VEGF-A165 iso-
form. The binding of VEGF-A165 to VEGFR2 and neuropilin1 is reported to enhance VEGFR
signaling by approximately a factor of ten. Coincidently, PKA activation increased the sensitiv-
ity of VEGFR2+ progenitors to VEGF, which increased the appearance of ECs also by a factor
of ten[17]. PKA is also directly involved in the EC commitment process. Etv2/ER71, an ETS
transcription factor, plays an indispensable role in EC and hematopoietic lineage commitment
from early mesoderm[18,19]. We previously showed that PKA-activated CREB (cyclic AMP-
responsive element (CRE) binding protein) bound to CRE on the Etv2/ER71 promoter region
and directly induced Etv2/ER71 expression[20]. In that same report, we also observed that
PKA activation during ESC differentiation triggered EC differentiation and induced early
commitment to EC lineage. In addition, we reported that Notch and β-catenin signaling are
simultaneously activated in the downstream of cAMP and protein complex formation with
Notch intracellular domain and β-catenin induced a set of arterial EC gene expressions
resulted in arterial EC differentiation[21]. These results indicate that VEGF is critical for EC
differentiation and growth, while cAMP is critical for EC commitment and specification.
With regards to human induced pluripotent stem cell (hiPSC) differentiation, we previously
reported an efficient cardiomyocyte (CM) differentiation method based on a 2D monolayer,
serum-free condition[22], that was modified from a directed differentiation protocol from
human ESCs[23]. In our method, we first induce mesoderm cells with Activin-A, bone mor-
phogenic protein 4 (BMP4), and basic fibroblast growth factor (bFGF), and then induced CM
commitment with a wnt inhibitor, Dickkopf-related protein 1 (DKK1). Inferring from our
mouse ESC results, we anticipated that fate control of mesoderm stage cells to EC lineage
should provide an efficient source of ECs. Therefore, in the present study, we investigated an
EC differentiation method from hiPSCs that combined differentiation stage-specific supple-
mentation of VEGF and cAMP. We further demonstrated that purification of EC-committed
cells at peri-EC stage, which can eliminate non-responder cells to EC differentiation ques,
achieved highly pure and efficient EC differentiation.
Materials and methods
hiPSC culture and differentiation
Three hiPSC lines, 201B6, 201B7 and 836B3, were used. 201B6 and 201B7 were established by
retroviral transduction using 4 factors: Oct3/4, Sox2, Klf4, and c-Myc[24]; 836B3 was estab-
lished by episomal plasmid vector transfection using 6 factors: Oct3/4, Sox2, Klf4, L-Myc,
LIN28 and Glis1[25]. 201B6 was used in all experiments except for the confirmation of multi-
ple cell lines. hiPSCs were maintained in a feeder-free condition with conditioned medium of
mouse embryonic fibroblasts (MEF-CM) supplemented with 4 ng/mL human basic fibroblast
growth factor (bFGF; WAKO, Tokyo, Japan) on thin-coated Matrigel (Growth factor reduced;
1:60 dilution; Corning, Corning, NY). MEF cells were plated at approximately 55,000 cells/cm2
in MEF medium (Dulbecco’s modified Eagle’s medium (DMEM) (Nakalai Tesque, Kyoto,
Japan) containing 10% fetal calf serum (FCS) (Thermo Fisher Scientific, Waltham, MA), 2
mM L-glutamine, 1% nonessential amino acids (NEAA) (Thermo Fisher Scientific)) followed
by treatment with mitomycin-C (MMC) (WAKO) for 2.5 hours. One day after plating, culture
medium was changed to ES medium (80% Knockout DMEM (Thermo Fisher Scientific), 20%
KSR (Thermo Fisher Scientific), 1 mM L-glutamine, 0.1 mM β-mercaptoethanol (Thermo
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Fisher Scientific), 1% NEAA, and 4 ng/mL hbFGF (WAKO); 0.5 mL/cm2), and MEF-CM was
collected daily for 1 week. hiPSCs were passaged every 4–6 days as small clumps using CTK
solution (0.1% Collagenase IV, 0.25% Trypsin (Thermo Fisher Scientific), 20% Knockout
serum replacement (KSR), and 1 mM CaCl2 in phosphate buffered saline (PBS)). The endothe-
lial differentiation process is summarized in Fig 1a. In detail, cells were dissociated using Ver-
sene (Thermo Fisher Scientific) for 3–5 min in an incubator at 37˚C and seeded onto Matrigel
thin-coated plates at 60,000 to 87,500 cells/cm2 in 1 mL of MEF-CM with 4 ng/mL of bFGF
four days before EC induction. Matrigel solution (1:60 dilution) was added to the cells 24
hours before EC induction. To induce endothelial differentiation, we replaced MEF-CM with
Fig 1. Efficient induction of endothelial cells from human pluripotent stem cells with supplementation of VEGF and cAMP. (a)
Schematic representation of the stimulation method. (b) Ratio of VE-Cadherin positive cell per total cells at differentiation day 9 by flow
cytometory in stimulation method group (VEGF+cAMP), VEGF administration groups (VEGF) and no administration groups (vehicle). (c)
Mean yield of endothelial cells per 1cm2 in three groups. (d) Distinct expression pattern of VE-cadherin in stimulation method at differentiation
day 9 (left panel) and post-VE-Cadherin purification (right panel).
https://doi.org/10.1371/journal.pone.0173271.g001
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RPMI+B27 medium (RPMI1640 (Thermo Fisher Scientific), 2 mM L-glutamine, 1xB27 sup-
plement without insulin (Thermo Fisher Scientific)) supplemented with 125 ng/mL of Activin
A (R&D Systems, Minneapolis, MN) and treated for 18 hours and then changed the culture
medium to 10 ng/ mL human bone morphogenetic protein 4 (BMP4; R&D), 10 ng/mL bFGF
and Matrigel (1:60 dilution) and treated for 3 days. The culture medium was subsequently
replaced with RPMI+B27 supplemented with 1 mM 8bromo-cAMP (Nakalai Tesque) and 100
ng/mL VEGF (WAKO) at differentiation day 4 (d(4)) and cultured for 3 days. The culture
medium was refreshed on d6. On d7, the culture medium was changed to RPMI+B27 with the
same dose of VEGF without 8bromo-cAMP and refreshed every 2 days.
HUVEC and HUAEC culture
Human Umbilical Vein Endothelial Cells (HUVECs) were from Lonza (Basel, Switzerland)
and maintained in EGM-2 medium (Lonza). Cells were isolated using 0.25%trypsin (Thermo
Fisher Scientific), then cultured on none-coated culture dish at 2,500–5,000 cells/cm2. Human
Umbilical Artery Endothelial Cells (HUAECs) (Promo Cell, Heidelberg, Germany) were cul-
tured in Endothelial Cell Growth Medium (Promo Cell). DetachKit (Promo Cell) were used
for digestion, and then the HUAECs were re-cultured at 4,000–5,000 cells/cm2. Cells were pas-
saged every 2-3days. At passage 3–5 cells were used for experiments.
Flow cytometry
On d(9), we dissociated the cells using Accumax (Innovative Cell Technologies, San Diego,
CA) and stained them with the cell surface markers listed in S1 Table. For cell surface markers,
staining was carried out in PBS with 5% FCS. To eliminate dead cells, cells were stained with
4’,6-diamidino-2- phenylindole (DAPI) for surface marker staining or with the LIVE/ DEAD
fixable Aqua Dead Cell Staining Kit (Thermo Fisher Scientific) for intracellular staining. For
intracellular proteins, staining was carried out on cells fixed with 4% paraformaldehyde (PFA)
in PBS. Cells were stained with the anti-cardiac isoform of Troponin T (TNNT2) (clone 13211,
Thermo Fisher scientific) labeled with Alexa-488 using Zenon technology (Thermo Fisher Sci-
entific). The staining was performed in PBS with 5% FCS and 0.75% Saponin (Sigma-Aldrich,
St. Louis, MO). Stained cells were analyzed on an AriaII flow cytometer (Becton Dickinson,
Franklin Lakes, NJ). After the selection of FSC/SSC gate, we additionally eliminated the dou-
blets by SSC-W/SSC-H gate and FSC-W/FSC-H gate. Data were collected from at least 10,000
events.
Evaluation of Vascular Endothelial (VE)-cadherin+ ECs at d(9)
At d(9), cells were dissociated using Accumax and stained with DAPI and VE-Cadherin. Stain-
ing was carried out in PBS with 5% FCS. Stained cells were examined and purified on an AriaII
flow cytometer. Viable cells were counted with the trypan blue-exclusion test. The yield of ECs
was calculated by multiplying the viable cell count with the percentage of ECs.
Purification and re-culture of VEGF Receptor-2 (VEGFR2)+ cells at d(6)
At d(6), cells were dissociated using Accumax and stained with DAPI and VEGFR2.
VEGFR2-positive cells were purified on an AriaII flow cytometer and then recultured at
10,000 VEGFR2+ cells/cm2 in RPMI+B27 medium with 1 mM 8bromo-cAMP, 100 ng/mL
VEGF and 10 μmol/L of a Rho-associated coiled-coil forming kinase inhibitor (Y-27632; Cal-
Biochem) on thin-coated Matrigel dishes. The culture medium was replaced to that supple-
mented with VEGF alone on d(7). On d(9), viable cells was counted by the trypan blue-
Endothelial cells from human iPS cells
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exclusion test. The purity of VE-cadherin and CD31 double-positive ECs was analyzed with a
flow cytometer.
Pure hiPSC-derived EC culture
hiPSC-derived ECs with more than 99% purity were obtained by the stimulation method or
stimulation-elimination method (see Results). hiPSC-derived ECs were plated on 1% gelatin-
coated dishes in human endothelial-serum free medium (SFM; Thermo Fisher Scientific) with
20 ng/mL bFGF, 10 ng/mL EGF, and 10 μg/mL human plasma fibronectin at 10,000 cells/cm2.
ECs grew at 80–90% confluency within 5–7 days.
Immunofluorescent imaging
Cells were fixed with 4% PFA and stained with antibodies shown in S1 Table. Nuclei were visu-
alized with DAPI (Thermo Fisher Scientific). Stained cells were photographed with an all-in-
one fluorescent microscopic system, Biorevo BZ-9000 (Keyence, Osaka, Japan).
Tube formation assay
Tube formation assay was performed as described previously[26]. Briefly, differentiated ECs (7
x 104) at d13 were plated on a 24-well plate (Thermo Fisher Scientific) coated with 300 μl
Matrigel Basement Membrane Matrix GFR (BD Biosciences), and cultured for 24 hrs.
LDL uptake
Assay of LDL uptake was performed as described previously[27]. Briefly, LDL uptake by cells
was assessed by fluorescent microscopy after incubation of the differentiated ECs with 10 μg/
ml acetylated LDL labeled with 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindo-carbocyanine per-
chlorate (DiI-Ac-LDL) (Biomedical Technologies, Stoughton, MA) for 4 h at 37˚C.
Arterial and venous EC culture
VEGFR2-positive cells in the stimulation-elimination method at d(6) were separated into four
groups. i) basal group: same as the stimulation-elimination method (VEGF from d(4) to d(9)
and 8bromo-cAMP from d(4) to d(6)), ii) extended cAMP group: extended 1mM 8bromo-
cAMP from d(7) to d(14), iii) Ang1 group: additional angiopoietin 1 from d(7) to d(9), and iv)
VEGF alone group: VEGF alone from d(4) to d(9). EC phenotypes were examined by FACS at
d(6), d(9), and d(14).
Quantitative reverse-transcription Polymerase Chain Reaction (qPCR)
Total RNA was extracted from purified ECs using RNeasy (QIAGEN, Hilden, Germany)
according to the manufacturer’s instructions. GAPDH was used to normalize gene expres-
sions. Quantitative PCR was performed using Power SYBR Green PCR Master Mix (Thermo
Fisher Scientific) on a StepOnePlus system (Thermo Fisher Scientific) with Delta Delta Ct
method. Forward and reverse primer sequences are shown in S2 Table.
Statistical analysis
At least three independent experiments were performed. Statistical analysis of the data was
performed with ANOVA. p< 0.05 was considered significant. Values are reported as
mean ± SD.
Endothelial cells from human iPS cells
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Results
Optimization of VEGF and cAMP supplementation
Previously, we established a monolayer high-density culture-based CM differentiation protocol
from hiPSCs[22,23]. In the present work, we attempted to induce ECs from hiPSCs by direct-
ing the fate of mesoderm-stage cells toward ECs mainly by VEGF and cAMP activation. Briefly,
mesoderm-stage cell induction process is as follows: undifferentiated hiPSCs maintained on
feeder-free condition were collected as single cells, and seeded on Matrigel-coated multi-well
plates 4 days prior to the initiation of differentiation (d(-4)). Matrigel overlay was conducted
when the culture became fully confluent (d(-1)) for 24 hours, then we initiated the differentia-
tion culture (d(0)). Mesoderm cells were induced with the addition of Activin-A (100 ng/mL)
from d(0) to d(1) followed by BMP4 (10 ng/mL) and bFGF (10 ng/mL) from d(1–5).
Then, various concentrations of VEGF and a cAMP analogue, 8-bromo-cAMP, were supple-
mented at time points around the possible mesoderm stage (d(5)), and the efficiency of vascular
endothelial (VE)-cadherin-positive EC induction on d(9) was evaluated with flow cytometry.
First, we examined the effects of VEGF. The addition of VEGF on d(5–9) dramatically induced
EC appearance compared with no VEGF. VEGF (100 ng/mL) stimulated efficient VE-cadherin+
EC appearance whereas VEGF at 200 ng/mL showed no apparent difference with VEGF 100
ng/mL (S1a Fig). The addition of VEGF on other days had less effect: VEGF stimulation from d
(0) stimulated less EC appearance, while starting VEGF treatment between d(3–5) resulted in a
plateau in EC induction efficiency and yield (S1b Fig). Next, we checked the effects of cAMP.
We added 8-bromo-cAMP at various concentrations (0.25–2 mM), time points (d(3–7)), and
periods (1–5 days) together with VEGF (100 ng/mL, d(5–9)). Compatible with our previous
results in mouse ESC studies, simultaneous stimulation of cAMP and VEGF enhanced EC
appearance from mesoderm stage cells (S1c Fig). Transient stimulation (d(4–6)) with 1 mM
8bromo-cAMP (arrows in S1c Fig) showed the most effective outcome both in efficiency
(53.6%) and yield (16.1×104 cells/cm2), suggesting that cAMP acts on EC commitment and
early EC differentiation processes, but has less effect at later stages. In our CM differentiation
protocol, cells are covered with Matrigel (Thermo Fisher Scientific) solution at d(-1) to stabilize
cell attachment[22]. Because cells became unstable after Activin-A treatment and massive cell
detachment often occurred during EC differentiation that caused the termination of experi-
ments, we added a secondary Matrigel overlay at d(1). This process successfully prevented mas-
sive detachment and loss of cells during EC differentiation and resulted in high EC yield. Small
modification in the Activin-A treatment (125 ng/mL, 18 hours treatment) further improved cell
attachment and EC appearance (data not shown). We adjusted the starting day of VEGF treat-
ment to d(4) (the same date as cAMP treatment) to simplify the protocol. Following these mod-
ifications, we established the first endothelial differentiation protocol called “stimulation
method” (Fig 1a). In summary, single dissociated hiPSCs are plated on Matrigel-coated dishes
at d(-4) (60,000 to 87,500 cells/cm2; input hiPSCs) and cultured in the maintenance condition.
The first Matrigel overlay is on d(-1), and on d(0), the medium is changed to differentiation
medium (RPMI1650 with B27 supplement). Then, Activin-A (125 ng/mL) is added for 18
hours followed by medium change with BMP4 (10 ng/mL) and bFGF (10 ng/mL) treatment
and the second Matrigel overlay. VEGF (100 ng/mL; d4-9) and 8bromo-cAMP (1.0 mM; d(4–
6)) treatments start on d(4). EC appearance is evaluated on d(9).
Evaluation of the stimulation method
Next, we evaluated the stimulation method by measuring EC differentiation. The addition of
both VEGF and 8bromo-cAMP were compared to those with VEGF alone or with neither
Endothelial cells from human iPS cells
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VEGF nor 8bromo-cAMP (vehicle). The efficiency of EC induction was evaluated with flow
cytometry on d(9). The VE-cadherin+ EC population was significantly increased with the
addition of VEGF and 8bromo-cAMP compared to VEGF alone or vehicle (56.2±12.5% vs.
11.8±7.2% vs. 2.3±2.4% of total cells, P = 0.000017, n = 4) (Fig 1b). The calculated EC count
was also notably increased following the VEGF and 8bromo-cAMP treatment (1.66±0.70×105
vs. 4.9±3.3×104 vs. 9.8±10.4×103 cells/cm2 culture surface, P = 0.0022, n = 4) (Fig 1c). On the
other hand, the cardiac troponin T+ CM population decreased with VEGF and 8bromo-cAMP
treatment (20.0±13.2% vs. 47.6±25.7% vs. 55.9±12.1% of total cells, P = 0.049, n = 4), while the
populations of Tra-1-60+ undifferentiated hiPSCs and platelet-derived growth factor receptor
β (PDGFRβ)-positive vascular mural cells were unchanged (S2 Fig). Overall, the cell popula-
tions on d(9) using the above protocol consisted of 60% VE-Cadherin+ ECs, 20% cTnT+ CMs,
5% PDGFRβ+ vascular mural cells, and 10% TRA1-60+ undifferentiated hiPSCs. Induced ECs
(up to 70%) were purified by FACS or MACS using anti-VE-cadherin and/or CD31 antibod-
ies, which provided ECs at more than 99% purity (Fig 1d).
Next, we examined the time course of cell differentiation. Appearance of Tra-1-60 (undif-
ferentiated hiPSCs), VEGFR2 (mesoderm and ECs), PDGFRα (mesoderm) VE-cadherin
(ECs), CD31 (ECs), PDGFRβ (mesoderm and mural cells), and VCAM1 (CMs) were exam-
ined by FACS from d(0) to d(10) with or without VEGF and 8bromo-cAMP. At d(2), almost
all cells were TRA-1-60+ undifferentiated iPSCs (S3 Fig). At d4, the number of TRA-1-60+
cells decreased and the mesoderm population (VEGFR2+, PDGFRα+, and PDGFRβ+) started
to appear. After the addition of VEGF and 8bromo-cAMP (d(4)), cell populations dramatically
changed (Fig 2a–2c). From d(6) to d(8), almost no ECs (VE-cadherin+/CD31+) appeared in
the vehicle condition (Fig 2a). Furthermore, VEGFR2 expression was decreased, PDGFR
expressions were sustained and VCAM1+ CMs were first observed from d(8) (S3 Fig). On the
other hand, in the VEGF and 8bromo-cAMP treatment group, ECs started to appear from d
(6) and became prominent on d(10) (Fig 2a). The VEGFR2+ population was maintained, but
the PDGFR+ populations gradually disappeared and almost no CMs (VCAM1+) were
observed. After d(8), VE-cadherin+/CD31+ cells made the majority of the cell population (Fig
2a). Furthermore, the percentage (70%) and total number of VE-cadherin+/CD31+ cells
peaked on d(8) (Figs 1d, 2b and 2c). However, total cell number peaked on d(6) and decreased
thereafter (Fig 2d). Thus, the stimulation method, which uses VEGF and cAMP stimulation,
successfully induced the EC fate from the mesoderm cells.
Despite the good effects of VEGF and cAMP on EC commitment, we noticed that not all
mesoderm cells responded and committed to EC lineage when we examined the time course
of VEGFR2+ mesoderm population (Fig 2e). VEGFR2+ mesoderm cells were induced by Acti-
vin-A/BMP4/bFGF treatment during d(0–4). In the control, VEGFR2+ cell population reached
maximum on d(5) and then decreased with almost no VE-cadherin+ EC appearance. On the
other hand, VEGF and 8bromo-cAMP treatment induced VE-cadherin+ ECs that maintained
VEGFR2 expression after d(6). While many cells started to express VE-cadherin on d(6), a
small population of cells remained negative for VEGFR2. These VEGFR2-negative cells never
disappeared even after EC differentiation (d(10))(arrows in Fig 2e), indicating that they did
not respond to EC commitment signaling. We speculated that these “non-responder cells”
should be a main cause of the contamination of non-ECs after EC differentiation with the
stimulation method.
Second EC differentiation protocol: Stimulation-elimination method
To further improve the EC induction efficiency, we therefore examined the elimination of
these non-responder cells at an early EC differentiation stage. We purified VEGFR2+ cells on
Endothelial cells from human iPS cells
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d6 with 99.0±0.5% purity (n = 7) and re-cultured them with VEGF and 8bromo-cAMP (Fig
3a). 8bromo-cAMP was withdrawn within one day (d(7)). On d(9), the responder cells gave
rise to ECs with more than 99% purity (Fig 3b). Moreover, the yield of ECs increased by a fac-
tor of four compared to the stimulation method, which did not include the elimination (0.68
±0.13 ECs vs. 4.20±0.83 ECs from 1 input hiPSC, n = 3) (Fig 3c). These results indicate that the
selection and re-culture of VEGFR2+ cells on d(6) successfully eliminates non-responder cells
and achieves almost complete EC induction from the responders. This second method, which
combines VEGF and cAMP stimulation with non-responder elimination (“stimulation-elimi-
nation” method), showed highly specific and efficient EC differentiation. Purified ECs on d(9)
induced with the stimulation-elimination method or stimulation method were similarly
expanded approximately 2.5 times after an additional 5-day culture in endothelial serum free
medium (Human Endothelial-SFM) (Fig 3d). This additional culture resulted in 11.1 ECs and
1.74 ECs per 1 input hiPSC on d(14) using the stimulation-elimination method and stimula-
tion method, respectively. ECs were replated at 10,000 cells/cm2 following dissociation with
Fig 2. Time course of endothelial cell and pre-endothelial cell marker. (a) Representative expression time course of VE-cadherin
(VECad) and CD31 under stimulation method (VEGF+cAMP) or vehicle without VEGF and cAMP by FACS. (b) Time course of
VE-Cadherin-positive cell ratio in two groups. (c) Yield of VE-Cadherin positive endothelial cells per 1cm2 in two groups. (d) Time course of
total cell counts in two groups. (e) Representative expression time course of VEGF receptor 2 (VEGFR2) and VE-cadherin in stimulation
method (VEGF+cAMP) or vehicle without cAMP and VEGF. Arrows: non-responder cells to VEGF and cAMP stimulation.
https://doi.org/10.1371/journal.pone.0173271.g002
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Fig 3. Stimulation-elimination method for efficient endothelial cells induction from human pluripotent stem cells. (a) Schematic
representation of stimulation-elimination method. (b) Distinct expression pattern of VE-cadherin (VECad) and CD31 in stimulation-
elimination method at differentiation day 9. (c) The yield of endothelial cells at differentiation day 9 from one human pluripotent stem cell in
stimulation method or stimulation-elimination method. (d) The yield of endothelial cells at differentiation day14 from one replated endothelial
cells at differentiation day 9 in two groups.
https://doi.org/10.1371/journal.pone.0173271.g003
Endothelial cells from human iPS cells
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Accumax (Innovative Cell Technologies) and grew to 80–90% confluence within 5 to 7 days of
culture. In many cases, ECs showed a tendency to cease growing following an additional one
to three passages in the human endothelial serum free medium condition. Occasionally, ECs
were able to continuously proliferated reaching approximately 103−104 times increase in 2
months of culture period. Induced ECs were cryopreserved using a freeze-preserving liquid
(Cellbanker III; Nippon Zenyaku Kogyo Co, Koriyama, Japan) on both d(9) and d(14).
Approximately two thirds of the plated cells survived the day after thawing and grew healthily
afterwards.
Robust differentiation in multiple hiPSC lines
We confirmed robust effectiveness of our differentiation methods in two other hiPSC lines,
201B7 and 836B3 cells (S4 Fig). In the stimulation method, addition of VEGF and 8bromo-
cAMP from the mesoderm stage (d(4)) significantly increased VE-cadherin+ EC percentages
compared with percentages in the VEGF only and vehicle groups on d9 (836B3, 51.2±8.5% vs.
28.3±6.9% vs. 4.7±3.9% of total cells, P = 0.0005, n = 3; and 201B7, 44.4±14.6%, 15.7±11.1%,
5.4±0.9% of total cells, P = 0.0100, n = 3), as well as the calculated EC counts (836B3, 2.79
±0.27×105 vs. 1.82±0.29×105 vs. 3.5±3.0×104 cells/cm2 culture surface, P = 0.0001, n = 3; and
201B7, 1.89±0.44×105 vs. 8.4±7.4×104 vs. 2.3±0.3×104 cells/cm2 culture surface, P = 0.0175,
n = 3). Similarly, the stimulation-elimination method was effective in multiple cell lines. After
purification and re-culturing of VEGFR2+ cells on d6, more than 99% efficiency of VE-cad-
herin+/CD31+ cells was achieved on d(9) from all cell lines examined. The elimination of non-
responder cells noticeably increased the yield of ECs compared between the stimulation-elimi-
nation and stimulation methods (836B3, 2.26±0.59 vs. 0.70±0.28 ECs from 1 hiPSC input,
P = 0.076, n = 3; and 201B7, 3.42±0.42 vs. 0.69±0.11 ECs from 1 hiPSC input, P = 0.0046,
n = 3). Thus, our methods were robust and effective in multiple hiPSC lines.
Characterization of hiPSC-derived ECs
hiPSC (201B6)-derived pure ECs were cultured on a gratin coated dish and positively immu-
nostained for the endothelial markers CD31 and VE-cadherin (Fig 4a and 4b). The mRNA
expression levels of the endothelial markers CD31, VE-cadherin and endothelial nitric oxide
synthase (eNOS) in hiPSC-derived ECs on d(9) were comparable to those in HUVECs
(human umbilical vein endothelial cells) and significantly higher than those in undifferentiated
hiPSCs (negative control)(Fig 4c–4e). CD34[28] and CD133[29] are markers of ECs as well as
multipotent progenitor cells, including immature hematopoietic stem cells and precursors of
endothelial cells[30,31]. CD34 and CD133 expression levels of hiPSC-derived ECs were higher
than those of HUVECs (Fig 4f and 4g). Though the expression levels had decreased during the
culturing of ECs, they were still higher than in HUVEC, even on d(30) (data not shown).
These results suggest that our methods achieve induction and maintenance of an early stage
ECs. We next tested tube formation assay. ECs (d(13)) successfully formed tube-like networks
on Matrigel (Fig 4h). These cells configuring tube formation were positive for CD31 (Fig 4i).
Uptake of low-density lipoproteins (LDLs), another EC function, was clearly displayed in
hiPSC-derived ECs (Fig 4j and 4k). The tube formation capacity and morphology were almost
comparable with those of HUVECs (S5 Fig). Those results suggest that hiPSC-derived ECs
with stimulation-elimination method are functional ECs.
Arterial and venous specification of hiPSC-derived EC
Previously, we reported that cAMP signaling is involved in arterial endothelial specification
through Notch and β-catenin activation in a mouse ES cell system[21]. Notch signal related-
Endothelial cells from human iPS cells
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Fig 4. Characterization of endothelial cell induced from human iPS cell with stimulation-elimination
method. Immunofluorescent staining for (a) CD31 (green) and (b) VE-Cadherin (red) in human iPS cell-derived
endothelial cells. Nuclei were visualized with DAPI (blue). (c-g) Relative mRNA log0 ratio in endothelial cells at
differentiation day 9 (EC (D9)) and undifferentiated human iPS cell (iPSC) compared with human umbilical vein
endothelial cell (HUVEC). CD31 (c), VE-Cadherin (d), eNOS (e), CD34 (f), and CD133 (g). (h) Tube formation
assay. Human iPS cell-derived endothelial cells were recultured on Matrigel Basement Membrane Matrix GFR
Endothelial cells from human iPS cells
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genes, including Notch1 and 4, Dll4, RBP-J, and Hey1/Hey2, are essential for arterial forma-
tion and vasculature development[32–36]. On the other hand, chicken ovalbumin upstream
promoter-transcription factor II (COUP-TFII) suppresses Notch signaling and regulates vein
identity[37]. We recently demonstrated that angiopoietin 1 induces venous ECs in coronary
vein formation in vivo and EC differentiation from mouse embryonic stem cells[38].
Then, we examined arterial-venous specification in human ECs induced from iPSCs. As
being speculated from that ECs are induced with VEGF and cAMP stimulation, ECs that
induced with our method were found to be initially induced with arterial features that show
13.5 times more mRNA expression for the arterial EC marker ephrinB2[39] than do human
umbilical artery endothelial cells (HUAECs) on d(9). However, following an additional 5-day
culture for EC expansion with no cAMP, ephrinB2 expression (d(14)) significantly decreased
but still higher than that in HUAECs (Fig 5a). Other arterial marker expressions, such as Dll1,
Dll4, and Notch1, were similarly high in ECs on d(9) and showed a tendency to decrease by d
(14) (S6 Fig). On the other hand, whereas the mRNA expression of a venous EC marker,
COUP-TFII[37] on d(9) was significantly lower than that in HUVECs, it returned to a compa-
rable level after EC expansion (Fig 5b). We previously showed that arterial-venous specifica-
tion was unstable in the early stage of ECs in a mouse ESC system[21]. Early ECs still possess
plasticity between arterial and venous phenotypes, and they can change their features from
arterial to venous and vice versa according to the culture conditions. Therefore, we speculated
that the ECs induced from hiPSCs in this study remained in an undetermined state for arterial
and venous ECs. Higher expressions of early stage EC markers CD34 and CD133 (Fig 4f and
4g) further support our speculation that ECs retain plasticity in EC diversity.
Next, we tried to control arterial and venous specification with various combinations of
small molecules or growth factors in our stimulation-elimination method (Fig 5c–5e). The
ratio of NRP1-positive cells at d6 in stimulation-elimination method or NRP1 and CXCR4
double positive ECs at d(9) were significantly increased compared to those with VEGF alone
(no cAMP) condition. At d(14), ECs with VEGF alone condition completely lost arterial
maker. Moreover, extended cAMP supplementation after d(7) had beneficial effect for arterial
specification at d(9) and d(14). The positive ratio of NRP1 and CXCR4 at d(9) was almost
comparable with those in HUAECs (human umbilical artery endothelial cells) (Fig 5e). On the
other hand, Supplementation of angiopoietin 1 after d(6) together with cAMP administration
during d(4) to d(6) significantly decreased the ratio of arterial EC population at d(9). Thus,
arterial-venous EC fates were able to be controlled during and after EC differentiation.
Discussion
In this study, we describe efficient and scalable EC differentiation methods based on a 2D
monolayer, serum-free culture system. Potent induction of EC commitment and differentia-
tion with cAMP and VEGF at the mesoderm stage dramatically shifted the fate of cells toward
ECs and achieved highly efficient EC induction. Moreover, the elimination of cells that had
not responded to EC commitment signals (non-responder cells) at the peri-EC stage (d(6))
resulted in almost 100% differentiation efficiency to ECs. The combination of differentiation
stage-specific signal stimulation and non-responder elimination (stimulation-elimination
coated dish. (i) Immunofluorescent stained of CD31 for recultured cells on Matrigel. (j,k) Acetyl-LDL
incorporation assay. Endothelial cells were incubated with acetylated LDL labeled with 1,1’-dioctadecyl-
3,3,3’,3’-tetramethylindo-carbocyanine perchlorate (DiI-Ac-LDL). Bright-field (j) and fluorescent (k) images.
Scale bars: 50 μm in (a), (b) and (i), 100 μm in (h), 200 μm in (j) and (k).
https://doi.org/10.1371/journal.pone.0173271.g004
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Fig 5. Arterial and venous specification of endothelial cells derived from human induced pluripotent stem cells
with supplementation of cAMP or angiopoetin1. (a,b) mRNA expression of arterial and venous endothelial cell maker in
endothelial cells derived from human iPS cell with stimulation-elimination method. Relative mRNA log10 ratio of EphrinB2
(a) and CoupTF2 (b) in endothelial cell induced from human iPS cell at differentiation day 9 (EC D9), at day14 (D14), human
iPSC and umbilical endothelial cells compared with HUVEC. †, significant difference compared with (a) HUAEC or (b)
HUVEC. §, significant difference compared with human iPS cell. (c) Schematic representation of the arterial and venous
specification methods. (d) Mean ratios of NRP1-positive cells in stimulation-elimination method groups (control) to no cAMP
group ((-)) at differentiation day 6. (e) Mean ratios of NRP1- CXCR4-double positive cells at differentiation day 9 and 14 in
control, extended cAMP groups (cAMP), angiopoetin1 groups (Ang1), no cAMP groups (-), and HUAECs / HUVECs (day 9
only). *P<0.05, **P<0.01, ***P<0.001.
https://doi.org/10.1371/journal.pone.0173271.g005
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method) is a highly efficient and scalable strategy for the pure induction of target cell
populations.
To generate a large-sized organ or tissue, blood vessels that are mainly formed by ECs are
necessary. For example, cardiac regeneration in humans after myocardial infarction is esti-
mated to require 108 to 109 cells[23,40–43]. Given that the percentage of the EC population to
total cells in an adult mouse heart is around 7%, 107 to 108 ECs would be required to realize
human heart regeneration by cell transplantation. Our method is calculated to be amenable to
prepare 108 ECs from just two 6-well plates robustly from several hiPSC lines, suggesting the
possibility to scale the delivery of ECs even at an industrial level.
ECs are key to 3D tissue engineering, because blood vessels are necessary for mature and
functional tissues and organs. ECs in vivo have been reported to have diverse phenotypes that
closely relate to the tissue and organ function, such as fenestrated ECs in bone marrow, sinu-
soidal ECs in liver[44], ECs in glomeruli and podocytes in kidney[45], and ECs involved in the
blood-brain barrier and astrocytes in brain[46]. Previously, various methods for induction of
ECs from human pluripotent stem cells were reported[47–51]. Lineage control and enhanced
EC differentiation with cAMP signaling combined with VEGF is our original method[16,17].
ECs induced by VEGF and cAMP showed plasticity between arterial and venous phenotypes
[21]. In addition, hiPSC-derived ECs induced with our method showed expression of imma-
ture EC markers (Fig 4f and 4g), suggesting that these ECs should possess a higher ability to
adjust to tissue-specific environments and diversify with appropriate function than do fully
differentiated EC sources such as HUVECs. Thus, our hiPSC-derived ECs should be more
suitable for the reconstitution of organ functions in vitro and in vivo. These results suggest
that our stimulation-elimination method, which efficiently and robustly differentiates hiPSCs
into ECs, is a potential technological basis for regenerative medicine and tissue engineering.
Supporting information
S1 Fig. Optimization of VEGF and cAMP supplementation. (a) Ratio of VE-Cadherin posi-
tive endothelial cells per total cells at differentiation day 9 with sustained addition of 0, 50 or
100 ng/ml VEGF (left) at differentiation day 3 to 9. Mean yield of endothelial cells per 1 cm2
in administration of each VEGF concentrations (right). (b) Ratio of endothelial cell per total
cells at differentiation day 9 with addition of 100 ng/ml VEGF from differentiation day 0–9
(Day0), 2–9 (Day2), 3–9 (Day3), 5–9 (Day5) or no administration of VEGF ((-)) together with
1.0 mM cAMP from differentiation day 5–6 (left). Mean yield of endothelial cells per 1cm2 in
each additional timing of VEGF or no administration of VEGF (right). (c) Ratio of VE-Cad-
herin positive cell per total cells at differentiation day 9 by flow cytometory with addition of
100 ng/ml VEGF from differentiation day 5 to day 9 together with various timing and concen-
tration of cAMP (Upper row). Mean yield of endothelial cells per 1cm2 in each administrated
condition of cAMP (Lower row).
(PDF)
S2 Fig. Ratio of cardiovascular cell and undifferentiated iPSC differentiated and induced
from iPSC cell with stimulation method. Ratio of (a) cardiac troponin T (cTnT), (b) Platelet-
Derived Growth Factor Receptor β (PDGFRβ) and (c) TRA-1-60 positive cell per total cells at
differentiation day 9 by with stimulation method (cAMP+VEGF), only VEGF administration
(VEGF) and no administration (vehicle). Mean yield of (d) cTnT-positive cardiomyocyte, (e)
PDGFRβ-positive vascular mural cell, (f) TRA-1-60 undifferentiated iPSC per 1cm2 in three
groups.
(PDF)
Endothelial cells from human iPS cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0173271 March 13, 2017 14 / 18
S3 Fig. Representative time course of cell surface marker. Expression time course of (a)
TRA-1-60 and CD31, (b) TRA-1-60 and CD31, (c) PDGF-Rβand VCAM-1 with stimulation
method (cAMP+VEGF) or control without cAMP and VEGF group (vehicle).
(PDF)
S4 Fig. Multi cell line confirmation of efficiency and scalability in stimulation method and
stimulation-elimination method. (a)(c) Ratio of VE-Cadherin-positive endothelial cells per
total cells at differentiation day 9 by flow cytometry with stimulation method (cAMP+VEGF),
only VEGF administration groups (VEGF) and no administration groups (vehicle) in other
two iPS cell lines (836B3, 207B7). (b)(d) Yield of endothelial cells per 1cm2 in two groups. (e)
(f) The yield of endothelial cells at differentiation day 9 from one hiPSC in stimulation method
or stimulation-elimination method.
(PDF)
S5 Fig. Tube formation assay and Acetyl-LDL incorporation assay in HUVECs. HUVECs
were recultured on Matrigel Basement Membrane Matrix GFR- coated dish (left upper).
Immunofluorescent stained of CD31 for recultured cells on Matrigel (right upper). Endothelial
cells were incubated with acetylated LDL labeled with 1,1’-dioctadecyl-3,3,3’,3’-tetramethy-
lindo-carbocyanine perchlorate (DiI-Ac-LDL) (lower). Bright-field (left) and fluorescent
(right) images. HUVEC, human umbilical vein endothelial cells. Scar bars: 200 μm.
(PDF)
S6 Fig. Relative expression of arterial markers in endothelial cells induced from human
iPSC with stimulation-elimination method. mRNA log10 ratio of Dll1 (a), Dll4 (b) and
Notch1 (c) at differentiation day 0 (D0), day 4 (D4), day 9 (D9) and day 14 (D14) compared
with human umbilical vein endothelial cell (HUVEC).
(PDF)
S1 Table. Fluorescence-conjugated monoclonal antibodies used for Immunofluorescence
Assay (IF) and FACS analysis.
(PDF)
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